Dr. Wiersinga is Professor of Medicine and chief of the Division of Infectious Diseases at the Department of Internal Medicine, Academic Medical Center, Amsterdam. In addition, he serves as clinical lecturer for biomedical science and medicine studies, and Principal Investigator at the Center for Experimental Molecular Medicine (CEMM), University of Amsterdam. His research centers on the pathogenesis of sepsis with a special interest in pneumonia, melioidosis and the gut microbiome. He is member of several guidelines on the management of patients with pneumonia and sepsis. Parameters of esteem include the ESCMID Young Investigator Award, the O'Callaghan PhD award and the Australian and New Zealand Intensive Care Society (ANZICS) Intensive Care Global Rising Star Award. He coordinates the EU Marie Curie ITN European Sepsis Academy.

Provides up-to-date information on the management of sepsis, including within the intensive care unit

Explains the use of biomarkers in the diagnosis and treatment of sepsis

Assists in the optimal use of antimicrobial therapy and adjunctive immunotherapy

Includes contributions from leading experts across the world

PART 1. SEPSIS: AN OVERVIEW:.-1. What is sepsis?.- 2. The epidemiology of sepsis.- PART 2. THE PATHOGENESIS OF SEPSIS:.- [...] pathogenesis.- [...] coagulation system in sepsis.-[...] endocrine system in sepsis.- 6.Biomarkers for sepsis.- PART 3.SEPSIS MANAGEMENT:.- 7.International clinical practice guidelines.- 8. Fluids.- 9.Vasopressors.- 10. Multiorgan failure.- 11.Importance of the pathogen.- 12.Antimicrobial therapy.- 13.Adjunctive immunotherapy.- PART IV. SEPSIS IN THE COMING DECADE:.- [...] trial design in sepsis.- 15. Sepsis in low- and middle income countries.- 16 Sepsis: the road ahead.